Analyst Ratings February 2, 2026

BMO Sticks with Outperform on Allstate, Sets $249 Target as Capital and Reinsurance Trends Shift

Analyst note highlights restored capital, lower reinsurance costs and potential buyback program refresh in 2026

By Sofia Navarro ALL
BMO Sticks with Outperform on Allstate, Sets $249 Target as Capital and Reinsurance Trends Shift
ALL

BMO Capital has reaffirmed an Outperform rating on Allstate and lifted its price target to $249.00, citing a recovered capital position after adjustments for Life & Health disposals and parent cash, a declining reinsurance expense outlook, and expectations that the insurer will refresh its share repurchase authorization in the first half of 2026. Other firms have also updated targets following changes to catastrophe loss and reinsurance assumptions.

Key Points

  • BMO Capital reaffirmed an Outperform rating on Allstate and set a $249.00 price target.
  • BMO says Allstate's capital position has fully recovered after adjustments for Life & Health sales and parent cash, supporting expectations for renewed share repurchases.
  • Reinsurance expense estimates were lowered as the insurer's annual reinsurance spend of over $1.1 billion is deflating; BMO expects an update on the program at earnings.

BMO Capital reiterated an Outperform rating and set a $249.00 price target on Allstate (NYSE:ALL) ahead of the insurer's scheduled earnings report on Wednesday. The firm's view accompanies data from InvestingPro that shows Allstate trading at a price-to-earnings ratio of 6.44 and appearing undervalued relative to Fair Value estimates.

In its research note, BMO Capital said Allstate's capital position has fully recovered when adjustments are made for the sale of the Life & Health business and for parent company cash levels. That restored capital footing underpins BMO's confidence in the stock and informs the firm's longer-term cash-return expectations.

BMO now expects Allstate to reload its share repurchase authorization during the first half of 2026. As a result, the research house increased its buyback estimates by roughly $700 million in total across 2026-2027.

The firm also trimmed its estimate for Allstate's reinsurance expense, noting that the company's substantial annual reinsurance outlay of more than $1.1 billion is deflating. BMO anticipates the company will provide an update on its reinsurance program when it reports earnings, which could indicate whether some of the reinsurance savings will be used to buy additional protection.


Recent catastrophe loss disclosures from Allstate were also highlighted. The company reported $80 million in catastrophe losses for December 2025, equal to $64 million after tax. For the fourth quarter, total catastrophe losses amounted to $209 million, or $165 million after tax. Separately, Allstate recorded $46 million in catastrophe losses for November 2025, which translated to $36 million after tax.

Other brokerages have adjusted their views and targets in light of updated loss and expense assumptions. BofA Securities lowered its price target to $293 from $313 while maintaining a Buy rating after reducing its forecast for pre-tax catastrophe losses, a change that increased its 2025 earnings-per-share forecast. BMO Capital raised its price target to $249, reflecting a 2% increase in its 2026/27 earnings-per-share estimate. Meanwhile, Evercore ISI kept an In Line rating with a $233 price target, citing solid performance despite growth concerns.

Taken together, these analyst moves provide a snapshot of how capital recovery, reinsurance dynamics and catastrophe loss experience are shaping market assessments of Allstate heading into the company's earnings release.

Risks

  • Catastrophe losses remain a variable - recent December and fourth-quarter catastrophe losses could continue to affect underwriting results and capital deployment; this primarily impacts the insurance sector and property-casualty markets.
  • Timing and scale of share repurchases are uncertain - although BMO expects a reload in the first half of 2026, actual authorization and execution could differ, affecting equity market sentiment.
  • Reinsurance program changes - decisions to use reinsurance savings to buy additional protection or retain savings could alter expense and risk-transfer dynamics for Allstate and influence reinsurance market participants.

More from Analyst Ratings

JPMorgan Lifts Chevron Price Target to $181, Citing Cost Cuts and Post-Merger Investment Phase Feb 2, 2026 H.C. Wainwright Sticks With Buy on Summit Therapeutics After FDA Accepts BLA Feb 2, 2026 Mizuho Lifts AXIS Capital Target After Strong 2025 Momentum Feb 2, 2026 JPMorgan Lifts ExxonMobil Target to $140 After Strong Q4 Results; Stock Near 52-Week High Feb 2, 2026 JPMorgan Reaffirms Overweight on Carvana, Cites Durable Online Advantage Feb 2, 2026